Company Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nyse Other stock markets 16:10:00 2024-05-10 EDT			5-day change	1st Jan Change
0.236 ^USD	+1.72%		+19.80%	-84.37%

04-16	Calidi Biotherapeutics Prices $6.1 Million Offering	MT
03-21	H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating	MT

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.

Number of employees: 41

Managers	Title	Age	Since
Allan Camaisa CEO	Chief Executive Officer	-	-
Andrew Jackson DFI	Director of Finance/CFO	55	23-10-29
Amish A. Patel CTO	Chief Tech/Sci/R&D Officer	47	22-07-31
Antonio Santidrian CTO	Chief Tech/Sci/R&D Officer	45	-
Wendy Pizarro ADM	Chief Administrative Officer	53	-
Boris Minev CTO	Chief Tech/Sci/R&D Officer	61	-
George Ng BRD	Director/Board Member	49	19-09-30
Stephen Thesing IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
George Ng BRD	Director/Board Member	49	19-09-30
Alan Stewart BRD	Director/Board Member	60	23-10-09
James Schoeneck BRD	Director/Board Member	66	-
Allan Camaisa CEO	Chief Executive Officer	-	-
Scott Leftwich BRD	Director/Board Member	-	-
David LaPré BRD	Director/Board Member	-	12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	35,726,784	16,092,971 ( 45.04 %)	0	45.04 %

Name	Equities	%	Valuation
Allan Camaisa 25.24 %	8,964,521	25.24 %	5 M $
Jackson Investment Group LLC 9.256 %	3,287,788	9.256 %	2 M $
Scott Leftwich 6.696 %	2,378,588	6.696 %	1 M $
Cable Car Capital LLC 1.517 %	538,860	1.517 %	304 456 $
Stephen Thesing 1.327 %	471,544	1.327 %	266 422 $
James Schoeneck 1.249 %	443,759	1.249 %	250 724 $
Boris Minev 1.195 %	424,458	1.195 %	239 819 $
First Light Acquisition Group LLC 0.9675 %	343,687	0.9675 %	194 183 $
Antonio Santidrian 0.9228 %	327,788	0.9228 %	185 200 $
Meteora Capital LLC 0.8131 %	288,826	0.8131 %	163 187 $

Name	Equities	%	Valuation
Polar Asset Management Partners, Inc. -	2,165,086	-	112 584 $
Highbridge Capital Management LLC -	1,627,956	-	84 654 $
Finepoint Capital LP -	655,200	-	34 070 $
683 Capital Management LLC -	600,000	-	31 200 $
Aristeia Capital LLC -	494,400	-	25 709 $
NOMURA HOLDINGS, INC. -	467,818	-	24 327 $
Shaolin Capital Management LLC -	450,000	-	23 400 $
Arena Investors LP -	333,333	-	17 333 $
Cowen & Co. LLC -	172,136	-	8 951 $
EHP Funds, Inc. -	107,964	-	5 614 $

Calidi Biotherapeutics, Inc.

4475 Executive Drive Suite 200

92121, San Diego

http://www.calidibio.com

address Calidi Biotherapeutics, Inc.(CLDI)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.236 USD

Average target price

3.25 USD

Spread / Average Target

+1,277.12%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CALIDI BIOTHERAPEUTICS, INC.	-84.37%	11.55M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs